195 related articles for article (PubMed ID: 28166182)
1. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
Bricout M; Petre A; Amini-Adle M; Bezza W; Seve P; Kodjikian L; Dalle S; Thomas L
J Immunother; 2017; 40(2):77-82. PubMed ID: 28166182
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
[TBL] [Abstract][Full Text] [Related]
4. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
5. Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis.
Shi T; Lv W; Zhang L; Chen J; Chen H
Sci Rep; 2014 Nov; 4():6887. PubMed ID: 25382027
[TBL] [Abstract][Full Text] [Related]
6. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.
Damico FM; Cunha-Neto E; Goldberg AC; Iwai LK; Marin ML; Hammer J; Kalil J; Yamamoto JH
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2465-71. PubMed ID: 15980237
[TBL] [Abstract][Full Text] [Related]
7. Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up.
Aisenbrey S; Lüke C; Ayertey HD; Grisanti S; Perniok A; Brunner R
Graefes Arch Clin Exp Ophthalmol; 2003 Dec; 241(12):996-9. PubMed ID: 14618342
[TBL] [Abstract][Full Text] [Related]
8. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.
Sugita S; Takase H; Taguchi C; Imai Y; Kamoi K; Kawaguchi T; Sugamoto Y; Futagami Y; Itoh K; Mochizuki M
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2547-54. PubMed ID: 16723469
[TBL] [Abstract][Full Text] [Related]
9. HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.
Takeuchi M; Meguro A; Nakamura J; Chikagawa R; Osada R; Shibuya E; Hasumi Y; Yamada N; Ishihara M; Mizuki N
Sci Rep; 2023 Aug; 13(1):13580. PubMed ID: 37604934
[TBL] [Abstract][Full Text] [Related]
10. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
[TBL] [Abstract][Full Text] [Related]
11. HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia.
Iqniebi A; Gaafar A; Sheereen A; Al-Suliman A; Mohamed G; Al-Hussein K; Tabbara KF
Mol Vis; 2009 Sep; 15():1876-80. PubMed ID: 19756183
[TBL] [Abstract][Full Text] [Related]
12. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
13. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
14. PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome.
Meng Q; Liu X; Yang P; Hou S; Du L; Zhou H; Kijlstra A
Mol Vis; 2009; 15():386-92. PubMed ID: 19234630
[TBL] [Abstract][Full Text] [Related]
15. [Association of HLA-DRB genes with Vogt-Koyanagi-Harada syndrome in a Chinese Han population].
Zhang M; Qiu C; Hu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):36-40. PubMed ID: 12903490
[TBL] [Abstract][Full Text] [Related]
16. [The association of HLA-DR4 gene subtypes with Vogt-Koyanagi-Harada syndrome].
Xiao T; Jiang Y; You X
Zhonghua Yan Ke Za Zhi; 1997 Jul; 33(4):268-71. PubMed ID: 10451958
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome.
Li K; Yang P; Zhao M; Hou S; Du L; Zhou H; Kijlstra A
Mol Vis; 2009 May; 15():955-61. PubMed ID: 19452015
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
Witmer MT
Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
[TBL] [Abstract][Full Text] [Related]
19. [Vitiligo revealing Vogt -Koyanagi-Harada disease].
Amraoui ME; Zemmez Y; Bouhamidi A; Frikh R; Hjira N; Boui M
Pan Afr Med J; 2017; 27():220. PubMed ID: 28979622
[TBL] [Abstract][Full Text] [Related]
20. Vogt-Koyanagi-Harada syndrome.
Greco A; Fusconi M; Gallo A; Turchetta R; Marinelli C; Macri GF; De Virgilio A; de Vincentiis M
Autoimmun Rev; 2013 Sep; 12(11):1033-8. PubMed ID: 23567866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
